Search company, investor...

Predict your next investment

Venture Capital
coltventures.com

Investments

17

Portfolio Exits

7

Funds

4

About Colt Ventures

Headquarters Location

2101 Cedar Springs Road

Dallas, Texas, 75201-2145,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Colt Ventures News

Odyssey Therapeutics: $101 Million Secured To Pioneer Next-Gen Precision Immunomodulators And Oncology Medicines

Dec 18, 2023

Odyssey Therapeutics – a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines – recently announced the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, including OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures LLC, The Healthcare Innovation Investment Fund LLC (an investment fund associated with Leerink Partners), Ab Magnitude Ventures, KB Investment, The Global BioAccess Fund, and multiple leading global investors. This Series C funding round brings the total capital raised since founding in late 2021 to $487 million. And the proceeds will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation. From its headquarters in Boston, Odyssey built a comprehensive drug discovery and development platform merging both computational and experimental technologies. This unique set of tools enables Odyssey to identify drug targets with the highest clinical potential in a modality-agnostic fashion. In just two years, the company has moved multiple programs forward from ideation to a portfolio of high-value product candidates. KEY QUOTES: “Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics with the goal of providing transformative medicines for large numbers of patients in need and several of these molecules have the potential to enter the clinic in the next 12 months. For us, success is defined as bringing safe and effective medicines to patients with serious diseases, with support from Ascenta and our other investors driving our pipeline into the future. We welcome Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital, to our board to join us in achieving this mission.” — Gary D. Glick, Ph.D., founder and CEO of Odyssey “Odyssey’s accomplished team of scientists and executives with numerous prior successes in discovery, development and commercialization has made tremendous progress in only two years. Dr. Glick has successfully created a sustainable and capital-efficient model that primes Odyssey to be a hub for immunology and oncology therapeutic innovation, and I look forward to working with him, the board and leaders on the management team in the years ahead.” — Lorence Kim, M.D. “Odyssey continues to accelerate multiple pre-clinical programs in immunology and oncology. By raising additional capital from world-class investors and adding a board member with expertise in drug development and company building, we are positioning Odyssey for success over the next several years as our pipeline enters clinical development.” — Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey board Sponsors

Colt Ventures Investments

17 Investments

Colt Ventures has made 17 investments. Their latest investment was in BlossomHill Therapeutics as part of their Series B on January 02, 2024.

CBI Logo

Colt Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/2/2024

Series B

BlossomHill Therapeutics

$88.65M

Yes

1

12/5/2023

Series C

Odyssey Therapeutics

$101M

No

7

11/2/2022

Series A - II

Alterome Therapeutics

$35M

Yes

5

10/13/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/2/2024

12/5/2023

11/2/2022

10/13/2022

12/7/2021

Round

Series B

Series C

Series A - II

Series B

Series A

Company

BlossomHill Therapeutics

Odyssey Therapeutics

Alterome Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$88.65M

$101M

$35M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

7

5

10

10

Colt Ventures Portfolio Exits

7 Portfolio Exits

Colt Ventures has 7 portfolio exits. Their latest portfolio exit was Rumble on September 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/16/2022

Reverse Merger

$99M

6

7/16/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/4/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/1/2013

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/16/2022

7/16/2021

12/4/2020

9/14/2018

11/1/2013

Exit

Reverse Merger

IPO

IPO

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Colt Ventures Fund History

4 Fund Histories

Colt Ventures has 4 funds, including Colt Ventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2002

Colt Ventures

Multi-Stage Venture Capital

Closed

$150M

1

12/31/1998

Vortex Ventures

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1997

Texcas Ventures

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1994

EFO Holdings

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2002

12/31/1998

12/31/1997

12/31/1994

Fund

Colt Ventures

Vortex Ventures

Texcas Ventures

EFO Holdings

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$150M

$99M

$99M

$99M

Sources

1

10

10

10

Colt Ventures Team

3 Team Members

Colt Ventures has 3 team members, including current Chief Operating Officer, Chad Hennings.

Name

Work History

Title

Status

Chad Hennings

Chief Operating Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Chad Hennings

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Operating Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.